Rik Ganguly

About

Rik Ganguly is a research scholar from North-Eastern Hill University in Shillong, India. He is currently working on bioinformatics and structural biology for drug discovery against atherosclerotic plaque instability. His research focuses on developing new approaches to understanding the molecular mechanisms underlying atherosclerosis and identifying potential targets for drug development. With a strong background in bioinformatics, Rik is passionate about leveraging cutting-edge computational tools and techniques to tackle complex biological problems. He has published several research papers in peer-reviewed journals and presented his work at various national and international conferences. In addition to his research, Rik is also involved in mentoring students and promoting science education in his community.

Employment

• Ashoka University Junior Engineer
  2024 - Present

Education

• North Eastern Hill University PhD
  2018 - 2024

Projects & Funding

Projects & funding information is unavailable.

Publications (11)

• In-silico drug repositioning studies of Candida albicans Nitrogen permease reactivator 1 (Npr1) kinase
  Scientific Reports 2025 DOI: 10.1038/s41598-025-08148-2
  +Save
• Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin A increases persistence and long-term anti-tumor activity
  Cell Reports Medicine 2025 DOI: 10.1016/j.xcrm.2025.102021
  +Save
• Selecting Optimal Molecular Interaction Settings and Identifying Key Biological Targets Through Enrichment Analysis and Data Mining
  Innovations in Sustainable Technologies and Computing 2025 DOI: 10.1007/978-981-97-6794-6_7
  +Save
• Herbal Medicine: History, Contemporary Use and the Future
  Herbs for Disease Prevention and Treatment 2024 DOI: 10.2174/9789815274882124010009
  +Save
• Identification of an inhibitor for atherosclerotic enzyme NOX-1 to inhibit ROS production
  Future Journal of Pharmaceutical Sciences 2023 DOI: 10.1186/S43094-023-00474-4
  +Save
• Designing of multi-epitope based vaccine against SARS COV-2, using reverse vaccinology approach
  International Journal of Pharmaceutical Sciences and Drug Research 2022 DOI: 10.25004/ijpsdr.2022.140415
  +Save
• Discovery of a novel inhibitor against urokinase-type plasminogen activator, a potential enzyme with a role in atherosclerotic plaque instability
  Journal of Biomolecular Structure and Dynamics 2022 DOI: 10.1080/07391102.2022.2051742
  +Save
• Topotecan and (22S)-Budesonide as potential Drug candidates against ORF3a in SARS-CoV-2 virus
  The NEHU Journal 2021
  +Save
• ZCPG, a cysteine protease from Zingiber montanum rhizome exhibits enhanced anti-inflammatory and acetylcholinesterase inhibition potential
  International Journal of Biological Macromolecules 2020 DOI: 10.1016/j.ijbiomac.2020.09.097
  +Save
• Atherosclerotic plaque development: Disease Pathogenesis and emergingtreatment options
  The NEHU Journal Vol. XVII, No. 1 (January - June) and No. 2 (July - December) 2019, pp. 108-124 2019
  +Save